These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10400729)

  • 1. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.
    Trkola A; Gordon C; Matthews J; Maxwell E; Ketas T; Czaplewski L; Proudfoot AE; Moore JP
    J Virol; 1999 Aug; 73(8):6370-9. PubMed ID: 10400729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity.
    Chang TL; Gordon CJ; Roscic-Mrkic B; Power C; Proudfoot AE; Moore JP; Trkola A
    J Virol; 2002 Mar; 76(5):2245-54. PubMed ID: 11836402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.
    Gordon CJ; Muesing MA; Proudfoot AE; Power CA; Moore JP; Trkola A
    J Virol; 1999 Jan; 73(1):684-94. PubMed ID: 9847374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection.
    Zhang YJ; Hatziioannou T; Zang T; Braaten D; Luban J; Goff SP; Bieniasz PD
    J Virol; 2002 Jun; 76(12):6332-43. PubMed ID: 12021366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
    Oberlin E; Amara A; Bachelerie F; Bessia C; Virelizier JL; Arenzana-Seisdedos F; Schwartz O; Heard JM; Clark-Lewis I; Legler DF; Loetscher M; Baggiolini M; Moser B
    Nature; 1996 Aug; 382(6594):833-5. PubMed ID: 8752281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional analysis of the RANTES-glycosaminoglycans interactions.
    Martin L; Blanpain C; Garnier P; Wittamer V; Parmentier M; Vita C
    Biochemistry; 2001 May; 40(21):6303-18. PubMed ID: 11371192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble glycosaminoglycans Do not potentiate RANTES antiviral activity on the infection of primary macrophages by human immunodeficiency virus type 1.
    Ylisastigui L; Bakri Y; Amzazi S; Gluckman JC; Benjouad A
    Virology; 2000 Dec; 278(2):412-22. PubMed ID: 11118364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling.
    Burns JM; Gallo RC; DeVico AL; Lewis GK
    J Exp Med; 1998 Nov; 188(10):1917-27. PubMed ID: 9815269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
    Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
    Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of biologically functional biotinylated RANTES.
    Vita C; Drakopoulou E; Ylisastigui L; Bakri Y; Vizzavona J; Martin L; Parmentier M; Gluckman JC; Benjouad A
    J Immunol Methods; 2002 Aug; 266(1-2):53-65. PubMed ID: 12133622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.
    Simmons G; Clapham PR; Picard L; Offord RE; Rosenkilde MM; Schwartz TW; Buser R; Wells TN; Proudfoot AE
    Science; 1997 Apr; 276(5310):276-9. PubMed ID: 9092481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.
    Xiao L; Rudolph DL; Owen SM; Spira TJ; Lal RB
    AIDS; 1998 Sep; 12(13):F137-43. PubMed ID: 9764773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.
    Techaarpornkul S; Collins PL; Peeples ME
    Virology; 2002 Mar; 294(2):296-304. PubMed ID: 12009871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of the putative heparan sulfate-binding motif BBXB of RANTES to transendothelial migration.
    Ali S; Fritchley SJ; Chaffey BT; Kirby JA
    Glycobiology; 2002 Sep; 12(9):535-43. PubMed ID: 12213786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity.
    Proudfoot AE; Fritchley S; Borlat F; Shaw JP; Vilbois F; Zwahlen C; Trkola A; Marchant D; Clapham PR; Wells TN
    J Biol Chem; 2001 Apr; 276(14):10620-6. PubMed ID: 11116158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor.
    Guan X; Chaffey PK; Chen H; Feng W; Wei X; Yang LM; Ruan Y; Wang X; Li Y; Barosh KB; Tran AH; Zhu J; Liang W; Zheng YT; Wang X; Tan Z
    Biochemistry; 2018 Jan; 57(1):136-148. PubMed ID: 29202246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
    Olson WC; Rabut GE; Nagashima KA; Tran DN; Anselma DJ; Monard SP; Segal JP; Thompson DA; Kajumo F; Guo Y; Moore JP; Maddon PJ; Dragic T
    J Virol; 1999 May; 73(5):4145-55. PubMed ID: 10196311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
    Owais M; Arya SK
    J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.